Sculptor Capital LP Takes $4.95 Million Position in Drugs Made In America Acquisition II Corp. $DMII

Sculptor Capital LP purchased a new stake in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 500,000 shares of the company’s stock, valued at approximately $4,950,000.

A number of other large investors have also made changes to their positions in DMII. Glazer Capital LLC purchased a new stake in shares of Drugs Made In America Acquisition II in the fourth quarter valued at approximately $23,264,000. First Trust Capital Management L.P. purchased a new stake in shares of Drugs Made In America Acquisition II in the fourth quarter valued at approximately $20,474,000. Hudson Bay Capital Management LP purchased a new stake in shares of Drugs Made In America Acquisition II in the fourth quarter valued at approximately $19,493,000. Wolverine Asset Management LLC purchased a new stake in shares of Drugs Made In America Acquisition II in the fourth quarter valued at approximately $10,521,000. Finally, Picton Mahoney Asset Management purchased a new stake in shares of Drugs Made In America Acquisition II in the fourth quarter valued at approximately $8,662,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on DMII shares. Wall Street Zen upgraded Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Weiss Ratings upgraded Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Drugs Made In America Acquisition II currently has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Stock Up 0.0%

Shares of Drugs Made In America Acquisition II stock opened at $10.09 on Tuesday. Drugs Made In America Acquisition II Corp. has a fifty-two week low of $9.86 and a fifty-two week high of $10.09. The stock has a 50 day simple moving average of $10.03.

About Drugs Made In America Acquisition II

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.